Diagnostic Performance of Deep Learning for Predicting Gliomas' IDH and 1p/19q Status in MRI: A Systematic Review and Meta-Analysis

Somayeh Farahani,Marjaneh Hejazi,Mehnaz Tabassum,Antonio Di Ieva,Neda Mahdavifar,Sidong Liu
2024-10-28
Abstract:Gliomas, the most common primary brain tumors, show high heterogeneity in histological and molecular characteristics. Accurate molecular profiling, like isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion, is critical for diagnosis, treatment, and prognosis. This review evaluates MRI-based deep learning (DL) models' efficacy in predicting these biomarkers. Following PRISMA guidelines, we systematically searched major databases (PubMed, Scopus, Ovid, and Web of Science) up to February 2024, screening studies that utilized DL to predict IDH and 1p/19q codeletion status from MRI data of glioma patients. We assessed the quality and risk of bias using the radiomics quality score and QUADAS-2 tool. Our meta-analysis used a bivariate model to compute pooled sensitivity, specificity, and meta-regression to assess inter-study heterogeneity. Of the 565 articles, 57 were selected for qualitative synthesis, and 52 underwent meta-analysis. The pooled estimates showed high diagnostic performance, with validation sensitivity, specificity, and area under the curve (AUC) of 0.84 [prediction interval (PI): 0.67-0.93, I2=51.10%, p < 0.05], 0.87 [PI: 0.49-0.98, I2=82.30%, p < 0.05], and 0.89 for IDH prediction, and 0.76 [PI: 0.28-0.96, I2=77.60%, p < 0.05], 0.85 [PI: 0.49-0.97, I2=80.30%, p < 0.05], and 0.90 for 1p/19q prediction, respectively. Meta-regression analyses revealed significant heterogeneity influenced by glioma grade, data source, inclusion of non-radiomics data, MRI sequences, segmentation and feature extraction methods, and validation techniques. DL models demonstrate strong potential in predicting molecular biomarkers from MRI scans, with significant variability influenced by technical and clinical factors. Thorough external validation is necessary to increase clinical utility.
Quantitative Methods,Artificial Intelligence,Machine Learning,Image and Video Processing
What problem does this paper attempt to address?
The problem this paper attempts to address is the evaluation of the diagnostic performance of deep learning (DL) models based on magnetic resonance imaging (MRI) in predicting isocitrate dehydrogenase (IDH) mutations and 1p/19q co-deletion status in gliomas. Specifically, the study aims to: 1. **Systematic Review and Meta-Analysis**: Conduct a systematic review and meta-analysis to comprehensively evaluate the effectiveness and reliability of existing MRI-based deep learning models in predicting IDH mutations and 1p/19q co-deletion status in gliomas. 2. **Impact of Technical Factors**: Investigate the impact of various technical factors (such as glioma grading, data sources, inclusion of non-imaging data, MRI sequences, segmentation and feature extraction methods, validation techniques, etc.) on the performance of deep learning models. 3. **Clinical Application Potential**: Assess the potential clinical application value of these deep learning models, particularly in improving the accuracy of predicting glioma molecular markers. 4. **Importance of External Validation**: Emphasize the importance of external validation in enhancing the clinical utility of the models and highlight some limitations in current research and directions for future studies. Through these objectives, the study hopes to provide scientific evidence for the non-invasive diagnosis of gliomas, thereby improving patient treatment and prognosis.